Hormone Therapy Timing and Chronic Disease Incidence in Primary Ovarian Insufficiency: A National Cohort Study.
While doctors know hormone therapy (HT) helps manage immediate symptoms and protects bones in POI, its long-term effects have yet to be fully examined. Researchers tracked over 21,000 women with POI and 84,000 similar women without POI between 2005 and 2015 in South Korea. They wanted to see if those with POI face a higher risk for chronic illnesses, like thyroid, heart, and bone diseases, and whether the specific timing of HT changes their long-term health outcomes.
The study was a retrospective cohort study, which means it used already collected data to answer their research questions. Lee and colleagues used the Korean National Health Insurance Service (NHIS) database, specifically focusing on a cohort of female employees. Because this data comes directly from official insurance health claims, it allowed researchers to track the long-term health journeys and prescriptions of a massive group of women over a decade.
Key findings:
- POI brings higher health risks: Those with POI naturally face a much higher baseline risk for chronic illnesses, including a 61% higher risk of cardiovascular disease, a 38% higher risk of type 2 diabetes, and more than double the risk of osteoporosis compared to women without POI.
- Hormone therapy: Those with POI who took HT saw reduced risk in high blood pressure and type 2 diabetes, with the lowest heart risks seen in women who stayed on the therapy the longest.
- On-time HT: Those who started HT "on time" (within 365 days of their diagnosis) had significantly lower rates of thyroid disease, type 2 diabetes, high cholesterol, and bone loss compared to those who delayed treatment (more than 365 days of their diagnosis).
Osteoporosis finding: Surprisingly, the data showed HT users had higher rates of osteoporosis diagnoses. However, researchers urge caution here: the database only tracked insurance claims, not actual bone density scans, meaning HT users might simply be getting checked by their doctors more often.
- Age and duration matter: The protective benefits of HT were strongest for women who took it for a long time. Conversely, those who started HT at an older age or used it only briefly actually showed an increased risk for health complications.
This study provides important evidence of the increased health risks associated with POI, demonstrating that its effects reach beyond reproductive health. However, there are a few important things to consider. Because this study looked at real-world insurance data and is a retrospective cohort, rather than a controlled clinical trial, it has several limitations. For example, the insurance claims cannot track exactly when POI symptoms first started. Moreover, the cohort was from those aged 20-79 years, which neglects pre-pubertal or teenage onset of POI. Finally, because it was not a randomised controlled clinical trial, we cannot infer anything more than association between HT use and outcomes.
Turning research into self-advocacy:
- This study proves that POI is much more than a fertility disorder, meaning you should ask your doctor for comprehensive screenings for thyroid health, blood pressure, and cholesterol, not just ovarian health.
- You know your body best, never hesitate to advocate for your health, push for answers, and seek out a strong medical support system.
https://academic.oup.com/humrep/article/38/6/1224/7109188?guestAccessKey=